KYTHERA Biopharmaceuticals, which is commercializing an injectable treatment for double chins with Bayer, raised $70 million by offering 4.4 million shares at $16, at high end of the range
Read More:
KYTHERA Biopharma prices upsized deal at $16, at high end of the range